nach oben

Tipp

Ketamin: Einsatz bei chronischen Schmerzen und Depression

Zeitschrift:: Wiener Medizinische Wochenschrift

Autoren:: Dr. Wolfgang Jaksch, MSc Prim. Univ.-Prof. Dr. Rudolf Likar, Prim. Ao.Univ.-Prof. Dr. Martin Aigner

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Zusammenfassung

Obwohl Ketamin seit langem bekannt und im klinischen Einsatz ist, bleiben nach wie vor Fragen rund um die vielfältigen möglichen Anwendungsfelder als Anästhetikum und Analgetikum offen. Diese betreffen nicht das klassische Einsatzgebiet in der Notfallmedizin und Anästhesie, sondern auch potentielle, neue Indikationen, in denen Ketamin in niedrigen, subanästhetischen Dosierungen zum Einsatz kommt. Der Wirkmechanismus am NMDA-Rezeptor unterscheidet Ketamin deutlich von allen anderen Analgetika. Mögliche Einsatzgebiete sind Prävention chronischer postoperativer Schmerzen sowie die Behandlung neuropathischer Schmerzen. Mit der Behandlung der refraktären Depression könnte sich Ketamin auch in einem gänzlich neuen Feld etablieren.

Annetta MG, Iemma D, Garisto C, et al. Ketamine: new indications for an old drug. Curr Drug Targets. 2005;6:789–94. CrossRef

Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;10:612. PubMedPubMedCentral

Peltoniemi MA, Hagelberg NM, Olkkola KT, et al. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059–77. CrossRef

Schoevers RA, Chaves TV, Balukova SM, et al. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry. 2016;208(2):108–13. CrossRef

Fanta S, Kinnunen M, Backman JT, et al. Population pharmacokinetics of S‑ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71:441–7. CrossRef

Chong C, Schug SA, Page-Sharp M, et al. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig. 2009;29:217–24. CrossRef

Christensen K, Rogers E, Green GA, et al. Safety and efficacy of intranasal ketamine for acute postoperative pain. Acute Pain. 2007;9:183–92. CrossRef

Pelissier T, Laurido C, Kramer V, et al. Antinociceptive interactions of ketamine with morphine or methadone in mononeuro-pathic rats. Eur J Pharmacol. 2003;477:23–8. CrossRef

Sleigh J, Harvey M, Voss L, et al. Ketamine—More mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4:76–81. CrossRef

10.

Salvadore G, Singh JB. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther. 2013;19(6):428–36. CrossRef

11.

Likar R, Jaksch W, Aigmüller T, et al. Interdisziplinäres Positionspapier „Perioperatives Schmerzmanagement“. Schmerz. 2017;31(5):463–82. CrossRef

12.

Benrath J, Brechtel C, Stark J, et al. Low dose of S(+)-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo. Br J Anaesth. 2005;95:518–23. CrossRef

13.

Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93:409–17. CrossRef

14.

Liu XG, Sandkühler J. Long-term potentiation of C‑fiber-evoked potentials in the rat spinal dorsal horn is prevented by spinal N‑methyl-D-aspartic acid receptor blockage. Neurosci Lett. 1995;191:43–6. CrossRef

15.

Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005;103(1):147–55. CrossRef

16.

Laskowski K, Stirling A, McKay WP, et al. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth. 2011;58(10):911–23. CrossRef

17.

Lavand’homme P, De Kock M, Waterloos H. Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery. Anesthesiology. 2005;103(4):813–20. CrossRef

18.

Himmelseher S, Durieux ME. Ketamine for perioperative pain management. Anesthesiology. 2005;102(1):211–20. CrossRef

19.

Jouguelet-Lacoste J, La Colla L, Schilling D, et al. The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature. Pain Med. 2015;16:383–403. CrossRef

20.

Kissin I, Bright CA, Bradley EL Jr.. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg. 2000;91:1483–8. CrossRef

21.

Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283–90. CrossRef

22.

Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg. 2003;96:789–95. CrossRef

23.

Lilius TO, Jokinen V, Neuvonen MS, et al. Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. Br J Pharmacol. 2015;172(11):2799–813. CrossRef

24.

Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618–25. CrossRef

25.

Schug SA, Pogatzki-Zahn EM. Chronic pain after surgery or injury. Pain 19(1):1–5.

26.

McNicol ED, Schumann R, Haroutounian S. A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain. Acta Anaesthesiol Scand. 2014;58:1199–213. CrossRef

27.

Hu J, Liao Q, Zhang F, et al. Chronic postthoracotomy pain and perioperative ketamine infusion. J Pain Palliat Care Pharmacother. 2014;28:117–21. CrossRef

28.

Tena B, Gomar C, Rios J. Perioperative epidural or intravenous ketamine does not improve the effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy. Clin J Pain. 2014;30:490–500. CrossRef

29.

Petrenko AB, Yamakura T, Baba H, et al. The role of N‑methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97:1108–16. CrossRef

30.

Niesters M, Khalili-Mahani N, Martini C, et al. Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo controlled functional magnetic resonance imaging study in healthy volunteers. Anesthesiology. 2012;117:868–77. CrossRef

31.

Niesters M, Aarts L, Sarton E, et al. Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo controlled cross-over study. Br J Anaesth. 2013;110(6):1010–6. CrossRef

32.

Rigo FK, Trevisan G, Godoy MC, et al. Management of neuropathic chronic pain with methadone combined with ketamine: a randomized, double blind, active-controlled clinical trial. Pain Physician. 2017;20:207–15. PubMed

33.

Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357–67. CrossRef

34.

Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145:304–11. CrossRef

35.

Lauritsen C, Mazuera S, Lipton RB, et al. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016;17:106. CrossRef

36.

Pomeroy JL, Marmura MJ, Nahas SJ, et al. Ketamine infusions for treatment refractory headache. Headache. 2017;57(2):276–82. CrossRef

37.

Zech DF, Grond S, Lynch J, et al. Validation of world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65–76. CrossRef

38.

Finkel JC, Pestieau SR, Quezado ZMN. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain. 2007;8(6):515–21. CrossRef

39.

Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30(29):3611–7. CrossRef

40.

Zgaia AO, Irimie A, Sandesc D, et al. The role of ketamine in the treatment of chronic cancer pain. Clujul Med. 2015;88(4):457–61. PubMedPubMedCentral

41.

Ripamonti CI, Santini D, Maranzano E, et al. ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii139–vii54. CrossRef

42.

Bell RF, Jaksch W, Kalso EA. Interpreting the evidence: reply to Spruyt et al. J Pain Symptom Manage. 2014;47(4):e2–e4. CrossRef

43.

Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a university of rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22(7):1807–14. CrossRef

44.

Naughton M, Clarke G, O’Leary OF, et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 2014;156:24–35. CrossRef

45.

Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134–42. CrossRef

46.

Swiatek KM, Jordan K, Coffman J. New use for an old drug: oral ketamine for treatment-resistant depression. BMJ Case Rep. 2016;3:2016.

47.

Irwin SA, Iglewicz A, Nelesen RA, et al. Daily oral Ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16(8):958–65. CrossRef

48.

Lally N, Nugent AC, Luckenbaugh DA, et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469. CrossRef

49.

Lally N, Nugent AC, Luckenbaugh DA, et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29(5):596–607. CrossRef

50.

McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693–704. CrossRef

51.

Bobo WV, Vande Voort JL, Croarkin PE, et al. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33(8):698–710. CrossRef

52.

Wilkinson ST, Sanacora G. Considerations on the off-label use of ketamine as a treatment for mood disorders. JAMA. 2017;318(9):793–4. CrossRef

53.

Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405. CrossRef

54.

Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–6. CrossRef

55.

Singh, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–26. CrossRef

56.

Fachinformation Ketanest®, Stand 06 (2017)

57.

Wang X, Ding X, Tong Y, et al. Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials. J Anesth. 2014;28(6):821–7. CrossRef

58.

Larsen R. Anästhesie. München, Jena: Elsevier, Urban & Fischer; 2010.

59.

Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;182:313–33. CrossRef

60.

Thiel H, Roewer N. Anästhesiologische Pharmakotherapie: von den Grundlagen der Pharmakologie zur Medikamentenpraxis. Stuttgart, New York: Thieme; 2009. CrossRef

61.

Tsai TH, Cha TL, Lin TT, et al. Ketamin-associated bladder dysfunction. Int J Urol. 2009;16:826–9. CrossRef

62.

Wood D, Cottrell A, Baker SC, Southgate J, et al. Recreational ketamine: from pleasure to pain. BJU Int. 2011;107(12):1881–4. CrossRef

63.

Jansen KLR. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32(4):419–33. CrossRef

Titel: Ketamin: Einsatz bei chronischen Schmerzen und Depression
Autoren:: Dr. Wolfgang Jaksch
MSc Prim. Univ.-Prof. Dr. Rudolf Likar
Prim. Ao.Univ.-Prof. Dr. Martin Aigner
Publikationsdatum: 12.04.2019
DOI: https://doi.org/10.1007/s10354-019-0695-x
Verlag: Springer Vienna
Zeitschrift: Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Hinweis des Verlags

Zusammenfassung